The IRB approval is a significant regulatory milestone for 60 Degrees Pharmaceuticals, indicating progress in the development of tafenoquine for babesiosis. This news is likely to be viewed positively by investors, as it suggests potential future revenue streams and growth for the company if the drug proves to be effective and reaches the market. The direct mention of the company and the nature of the news suggest a high relevance and importance to the stock. The confidence in the analysis is high due to the clear cause-and-effect relationship between regulatory milestones and stock price movements in the biotech industry.